Cost of illness: acute coronary syndrome in Switzerland
At a glance
- Project leader : Prof. Dr. Klaus Eichler, Prof. Dr. Simon Wieser
- Project budget : CHF 100'000
- Project status : completed
- Funding partner : Third party (Astra Zeneca)
- Contact person : Klaus Eichler
QUESTIONS UNDER STUDY: To perform a cost-of-illness study of
acute coronary syndrome (ACS) in Switzerland from a societal
perspective, evaluating direct costs, production losses and
intangible costs in terms of quality adjusted life years (QALYs)
METHODS: A bottom-up incidence-based approach was used. Data concerning patients with one or more ACS
events were extracted from a national hospital database and from mortality statistics. Inpatient costs included acute care and rehabilitation. Outpatient costs included costs for ambulance, visits to GP and cardiologist, outpatient diagnostics, medication and rehabilitation. Production losses included absenteeism, permanent disability and premature death. Intangible costs were calculated on previously published QALY weights. Cost data were derived from official price lists, literature and experts. Future costs and QALYs lost were discounted.
RESULTS: In 2008 14,955 patients experienced a total of 16,815 ACS events; 2,752 died as a consequence of these. The resulting 19,064 hospital stays had an average acrosshospital length of stay of 9.1 days per patient. Total direct costs of ACS amounted to 630 Mio Swiss Francs (CHF) for society and CHF 462 Mio for health insurers. Total direct costs were dominated by costs of myocardial infarction: ST-elevation 45.8%, non-ST-elevation 35.8%. Production losses were CHF 519 Mio and intangible costs resulted in
49,878 QALYs lost.
CONCLUSIONS: ACS causes considerable costs in terms of direct medical expenditures, lost production, suffering and premature death, even without taking into account costs for its chronic consequences such as congestive heart failure.